CLPTClearPoint Neuro, Inc.同业对比
ClearPoint Neuro, Inc. 与SIC 3841 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLPT本股 | $436M#5 | — | 23.1x#10 | 11.8x#9 | 17.8%#4 | -35.0%#10 | -65.4%#9 | -135.6%#7 | — | — | 37.6%#2 | — |
| ADGM | $11M#10 | — | 1.9x#4 | — | — | — | — | -438.1%#10 | -139.5%#8 | — | -72.2%#3 | — |
| AEMD | $1M#12 | — | 0.3x#1 | — | -100.0%#14 | 46.6%#6 | — | -146.4%#8 | — | — | — | — |
| ALRTF | — | — | — | — | 978.8%#1 | -38.9%#11 | 16719.9%#1 | — | — | — | — | — |
| ALUR | $10M#11 | — | — | 0.7x#2 | -52.6%#11 | -299.5%#13 | -198.0%#11 | — | — | 2#9 | — | — |
| ALURD | — | — | — | — | -52.6%#11 | -299.5%#13 | -198.0%#11 | — | — | 2#9 | — | — |
| ALURW | — | — | — | — | -52.6%#11 | -299.5%#13 | -198.0%#11 | — | — | 2#9 | — | — |
| AMIX | $49M#8 | — | 8.4x#8 | — | — | -46.5%#12 | — | -283.5%#9 | -1150.9%#9 | — | — | — |
| ANGO | $592M#4 | — | 3.5x#6 | 1.8x#5 | 9.5%#8 | -8.1%#8 | -12.5%#8 | -21.5%#5 | -16.5%#5 | 4#7 | — | — |
| ANIK | $204M#6 | — | 1.5x#3 | 1.8x#3 | -5.9%#10 | 80.4%#3 | -9.8%#5 | -8.0%#4 | -8.8%#4 | 4#7 | — | — |
| AORT | $1.3B#3 | 108.1x#1 | 2.9x#5 | 3.0x#6 | 13.6%#6 | 173.1%#1 | 7.6%#2 | 2.2%#1 | 3.7%#1 | 7#1 | — | 0.3%#1 |
| APYX | $161M#7 | — | 12.6x#9 | 3.1x#7 | 9.9%#7 | 52.2%#5 | -12.2%#7 | -87.4%#6 | -25.1%#7 | 6#3 | 96.4%#1 | — |
| ARAY | $29M#9 | — | 0.7x#2 | 0.1x#1 | 2.7%#9 | 89.8%#2 | 1.7%#3 | -3.8%#3 | 0.0%#2 | 6#3 | — | — |
| ATEC | $1.4B#2 | — | — | 1.8x#4 | 25.0%#3 | 11.6%#7 | -10.7%#6 | — | -19.2%#6 | 6#3 | — | — |
| ATRC | $2.0B#1 | 189.4x#2 | 3.9x#7 | 3.8x#8 | 14.9%#5 | 74.4%#4 | -1.8%#4 | -2.2%#2 | -2.3%#3 | 7#1 | — | — |
| AURX | — | — | — | — | 142.7%#2 | -8.1%#9 | -76.0%#10 | — | — | 5#6 | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-07-30。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议